Multitargeted polypharmacotherapy for cancer treatment. theoretical concepts and proposals

References

• Skurvydas A. Paradigm errors in the old biomedical science. Medicina (Kaunas). 2008;44(5):356–365. doi: 10.3390/medicina44050046
   PubMed Web of Science ®Google Scholar
• Mittra I. Why is modern medicine stuck in a rut? Perspect Biol Med. 2009;52(4):500–517. doi: 10.1353/pbm.0.0131
   PubMed Web of Science ®Google Scholar
• Darrow JJ. Two views of cancer medicines: imagery versus evidence. Health Mark Q. 2023;40(2):141–152. doi: 10.1080/07359683.2021.1997512
   PubMedGoogle Scholar
• Wang MTM, Grey A, Bolland MJ. Conflicts of interest and expertise of independent commenters in news stories about medical research. Can Med Assoc J. 2017;189:E553–9. doi: 10.1503/cmaj.160538
   Web of Science ®Google Scholar
• Schnog J-J, Samson MJ, Duits AJ. Financial conflict of interest and anti-cancer drugs: why the NTVG’s stance to exclude pharma-advertisement is of importance. Ned Tijdschr Geneeskd. 2022 Jul 28;166:D6738.
   PubMedGoogle Scholar
• Maeda H, Khatami M. Analyses of repeated failures in cancer therapy for solid tumors: poor tumor‐selective drug delivery, low therapeutic efficacy and unsustainable costs. Clinical & Translational Med. 2018;7(1):7. doi: 10.1186/s40169-018-0185-6
   PubMedGoogle Scholar
• Horgan J. Scientific American. Cancer industry hype vs reality. 2020. https://www.scientificamerican.com/blog/cross-check/the-cancer-industry-hype-vs-reality/
   Google Scholar
• Shulman LN, Wagner CM, Barr R, et al. Proposing essential medicines to treat cancer: methodologies, processes, and outcomes. J Clin Oncol. 2016;34:69–75. doi: 10.1200/JCO.2015.61.8736
   PubMed Web of Science ®Google Scholar
• Michaeli DT, Michaeli T. Overall survival, progression-free survival, and tumor response benefit supporting initial US food and drug administration approval and indication extension of new cancer drugs, 2003-2021. J Clin Oncol. 2022;40:4095–4106. doi: 10.1200/JCO.22.00535
   PubMed Web of Science ®Google Scholar
• Petrou P. Assessing the pricing and benefits of oncology products: an update. Expert Rev Pharmacoecon Outcomes Res. 2021;21:335–342. doi: 10.1080/14737167.2021.1926987
   PubMed Web of Science ®Google Scholar
• Abola MV, Prasad V. The Use of superlatives in cancer research. JAMA Oncol. 2016;2(1):139. doi: 10.1001/jamaoncol.2015.3931
   PubMed Web of Science ®Google Scholar
• Hilal T, Sonbol MB, Prasad V. Analysis of control arm quality in randomized clinical trials leading to anticancer drug approval by the US food and drug administration. JAMA Oncol. 2019;5(6):887. doi: 10.1001/jamaoncol.2019.0167
   PubMed Web of Science ®Google Scholar
• Gyawali B, Rome BN, Kesselheim AS. Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study. BMJ. 2021;2021:n1959. doi: 10.1136/bmj.n1959
   Google Scholar
• Lu E, Shatzel J, Shin F, et al. What constitutes an “unmet medical need” in oncology? An empirical evaluation of author usage in the biomedical literature. Semin Oncol. 2017;44(1):8–12. doi: 10.1053/j.seminoncol.2017.02.009
   PubMed Web of Science ®Google Scholar
• Braillon A, Blumsohn A. Regulatory drug approval: protecting patients or serving impatient shareholders? BMJ. 2021;2021:n2382. doi: 10.1136/bmj.n2382
   Google Scholar
• IQVIA. n.d. Available from: https://www.iqvia.com/insights/the-iqvia-institute/reports/global-oncology-trends-2022
   Google Scholar
• Lavietes MH, Reddi AS. Basic biomedical science and the destruction of the pathophysiologic bridge from bench to bedside. Am J Med. 2000;109:171–172. doi: 10.1016/S0002-9343(00)00354-5
   PubMed Web of Science ®Google Scholar
• Feinstein AR. Basic biomedical science and the destruction of the pathophysiologic bridge from bench to bedside. Am J Med. 1999;107:461–467. doi: 10.1016/S0002-9343(99)00264-8
   PubMed Web of Science ®Google Scholar
• Tape C. The institute of cancer research. Escape from Reductionist Val ICER. 2016. Available from: https://www.icr.ac.uk/blogs/the-bigger-picture/page-details/escape-from-reductionist-valley
   Google Scholar
• Soto AM, Sonnenschein C. The somatic mutation theory of cancer: growing problems with the paradigm? BioEssays. 2004;26(10):1097–1107. doi: 10.1002/bies.20087
   PubMed Web of Science ®Google Scholar
• Baker SG. A cancer theory kerfuffle can lead to new lines of research. J Natl Cancer Inst. 2015;107(2):dju405–dju405. doi: 10.1093/jnci/dju405
   PubMedGoogle Scholar
• Brücher BLDM, Jamall IS. Somatic mutation theory - why it’s wrong for most cancers. Cell Physiol Biochem. 2016;38(5):1663–1680. doi: 10.1159/000443106
   PubMedGoogle Scholar
• Griffin S. Diabetes precision medicine: plenty of potential, pitfalls and perils but not yet ready for prime time. Diabetologia. 2022;65(11):1913–1921. doi: 10.1007/s00125-022-05782-7
   PubMed Web of Science ®Google Scholar
• Tada H, Usui S, Sakata K, et al. Challenges of precision medicine for atherosclerotic cardiovascular disease based on human genome information. J Atheroscler Thromb. 2021;28:305–313. doi: 10.5551/jat.60087
   PubMed Web of Science ®Google Scholar
• Pathak N, Vimal SK, Tandon I, et al. Neurodegenerative disorders of Alzheimer, parkinsonism, amyotrophic lateral sclerosis and multiple sclerosis: an early diagnostic approach for precision treatment. Metab Brain Dis. 2022;37(1):67–104. doi: 10.1007/s11011-021-00800-w
   PubMed Web of Science ®Google Scholar
• Kato S, Lippman SM, Flaherty KT, et al. The conundrum of genetic “drivers” in benign conditions. JNCI J Natl Cancer Inst. 2016;108(8):djw036. doi: 10.1093/jnci/djw036
   Web of Science ®Google Scholar
• Acha-Sagredo A, Ganguli P, Ciccarelli FD. Somatic variation in normal tissues: friend or foe of cancer early detection? Ann Oncol. 2022;33:1239–1249. doi: 10.1016/j.annonc.2022.09.156
   PubMed Web of Science ®Google Scholar
• Jain P, Kantarjian H, Alattar ML, et al. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials. Lancet Haematol. 2015;2:e118–28. doi: 10.1016/S2352-3026(15)00021-6
   PubMed Web of Science ®Google Scholar
• Kopetz S, Desai J, Chan E, et al. Phase II pilot study of vemurafenib in patients with metastatic BRAF -Mutated colorectal cancer. J Clin Oncol. 2015;33:4032–4038. doi: 10.1200/JCO.2015.63.2497
   PubMed Web of Science ®Google Scholar
• de Langen AJ, Johnson ML, Mazieres J, et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial. Lancet. 2023;401(10378):733–746. doi: 10.1016/S0140-6736(23)00221-0
   PubMed Web of Science ®Google Scholar
• Olivier T, Haslam A, Prasad V. Sotorasib in KRASG12C mutated lung cancer: can we rule out cracking KRAS led to worse overall survival? Transl Oncol. 2023;28:101591. doi: 10.1016/j.tranon.2022.101591
   PubMed Web of Science ®Google Scholar
• Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883–892. doi: 10.1056/NEJMoa1113205
   PubMed Web of Science ®Google Scholar
• Normanno N, Rachiglio AM, Lambiase M, et al. Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial. Ann Oncol. 2015;26:1710–1714. doi: 10.1093/annonc/mdv176
   PubMedGoogle Scholar
• Talaat IM, Kim B. A brief glimpse of a tangled web in a small world: tumor microenvironment. Front Med. 2022;9. doi: 10.3389/fmed.2022.1002715
   Web of Science ®Google Scholar
• Bukhari I, Zhang Y, Thorne RF, et al. Editorial: complexity of tumor microenvironment: a major culprit in cancer development. Front Endocrinol. 2022 13;13. doi: 10.3389/fendo.2022.1059885
   Web of Science ®Google Scholar
• Greenhalgh J, Dwan K, Boland A, et al. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. Cochrane Database Syst Rev. 2016. doi: 10.1002/14651858.CD010383.pub2
   Web of Science ®Google Scholar
• Tuccori M, Montagnani S, Capogrosso-Sansone A, et al. Adverse reactions to oncologic drugs: spontaneous reporting and signal detection. Expert Rev Clin Pharmacol. 2015;8:61–75. doi: 10.1586/17512433.2015.974555
   PubMed Web of Science ®Google Scholar
• Wang Z, Yang X, Wang J, et al. Risk of serious adverse event and fatal adverse event with molecular target anticancer drugs in cancer patients: a meta-analysis. J Cancer Res Ther. 2019;15:1435. doi: 10.4103/jcrt.JCRT_577_18
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Stroyakovskiy D, Gogas H, et al. Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study. Lancet Oncol. 2023;24:33–44. doi: 10.1016/S1470-2045(22)00687-8
   PubMed Web of Science ®Google Scholar
• Fahey CC, Shevach JW, Flippot R, et al. Triplet strategies in metastatic clear cell renal cell carcinoma: a worthy option in the first-line setting? Am Soc Clin Oncol Educ B. 2023. doi: 10.1200/EDBK_389650
   PubMedGoogle Scholar
• Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer. N Engl J Med. 2019;381(17):1632–1643. doi: 10.1056/NEJMoa1908075
   PubMed Web of Science ®Google Scholar
• Fu W, Bang S-M, Huang H, et al. Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible asian patients with newly diagnosed multiple myeloma: the phase 3 OCTANS study. Clinical Lymphoma Myeloma And Leukemia. 2023;23(6):446–455.e4. doi: 10.1016/j.clml.2023.02.009
   PubMed Web of Science ®Google Scholar
• Linley AJ, Karydis LI, Mondru AK, et al. Kinobead profiling reveals reprogramming of BCR signaling in response to therapy within primary CLL cells. Clin Cancer Res. 2021;27:5647–5659. doi: 10.1158/1078-0432.CCR-21-0161
   PubMed Web of Science ®Google Scholar
• Johnson GL, Stuhlmiller TJ, Angus SP, et al. Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF–MEK–ERK pathway in cancer. Clin Cancer Res. 2014;20:2516–2522. doi: 10.1158/1078-0432.CCR-13-1081
   PubMedGoogle Scholar
• Liu S, Nikanjam M, Kurzrock R. Dosing de novo combinations of two targeted drugs: towards a customized precision medicine approach to advanced cancers. Oncotarget. 2016;7(10):11310–11320. doi: 10.18632/oncotarget.7023
   PubMedGoogle Scholar
• Tannock IF, Hickman JA. Limits to personalized cancer medicine. N Engl J Med. 2016;375(13):1289–1294. doi: 10.1056/NEJMsb1607705
   PubMed Web of Science ®Google Scholar
• Rosenfeld S. Biomolecular self-defense and futility of high-specificity therapeutic targeting. Gene Regul Syst Bio. 2011;5:89–104. doi: 10.4137/GRSB.S8542
   PubMedGoogle Scholar
• Tian T, Olson S, Whitacre JM, et al. The origins of cancer robustness and evolvability. Integr Biol. 2011;3:17–30. doi: 10.1039/C0IB00046A
   Google Scholar
• Whitacre J, Bender A. Degeneracy: a design principle for achieving robustness and evolvability. J Theor Biol. 2010;263:143–153. doi: 10.1016/j.jtbi.2009.11.008
   PubMed Web of Science ®Google Scholar
• Kitano H. Cancer as a robust system: implications for anticancer therapy. Nat Rev Cancer. 2004;4(3):227–235. doi: 10.1038/nrc1300
   PubMed Web of Science ®Google Scholar
• Agoston V, Csermely P, Pongor S. Multiple weak hits confuse complex systems: a transcriptional regulatory network as an example. Phys Rev E. 2005;71(5):71. doi: 10.1103/PhysRevE.71.051909
   Web of Science ®Google Scholar
• Carlson JM, Doyle J. Highly optimized tolerance: robustness and design in complex systems. Phys Rev Lett. 2000;84(11):2529–2532. doi: 10.1103/PhysRevLett.84.2529
   PubMed Web of Science ®Google Scholar
• Csete ME, Doyle JC. Reverse engineering of biological complexity. Science. 2002;295(5560):1664–1669. doi: 10.1126/science.1069981
   PubMed Web of Science ®Google Scholar
• Mencher SK, Wang LG. Promiscuous drugs compared to selective drugs (promiscuity can be a virtue). BMC Clin Pharmacol. 2005;5(1):3. doi: 10.1186/1472-6904-5-3
   PubMedGoogle Scholar
• Frei E. The national cancer chemotherapy program. Science. 1982;217(4560):600–606. doi: 10.1126/science.7046055
   PubMed Web of Science ®Google Scholar
• Hargrave-Thomas E. Serendipity in anticancer drug discovery. World J Clin Oncol. 2012;3(1):1. doi: 10.5306/wjco.v3.i1.1
   PubMedGoogle Scholar
• Ryszkiewicz P, Malinowska B, Schlicker E. Polypharmacology: promises and new drugs in 2022. Pharmacol Rep. 2023;75(4):755–770. doi: 10.1007/s43440-023-00501-4
   PubMed Web of Science ®Google Scholar
• World Health Organization. Medication safety in polypharmacy. 2019 [cited 2023 Apr 19]:1–63. https://www.who.int/publications/i/item/WHO-UHC-SDS-2019.11
   Google Scholar
• Masnoon N, Shakib S, Kalisch-Ellett L, et al. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230. doi: 10.1186/s12877-017-0621-2
   PubMed Web of Science ®Google Scholar
• National Library of Medicine. n.d [cited 2023 Apr 19]. Available from: https://www.ncbi.nlm.nih.gov/mesh/?term=polypharmacology
   Google Scholar
• Kabir A, Muth A. Polypharmacology: the science of multi-targeting molecules. Pharmacol Res. 2022;176:106055. doi: 10.1016/j.phrs.2021.106055
   PubMed Web of Science ®Google Scholar
• Scotti MT, Scotti L, dos Santos AMF. Challenges and discoveries in polypharmacology of neurodegenerative diseases. CTMC. 2023;23(5):349–370. doi: 10.2174/156802662305230217155933
   Google Scholar
• Frei E. Curative cancer chemotherapy. Cancer Res. 1985;45(12 Pt 1):6523–6537.
   PubMed Web of Science ®Google Scholar
• DeVita VT, Chu E. A history of cancer chemotherapy. Cancer Res. 2008;68:8643–8653. doi: 10.1158/0008-5472.CAN-07-6611
   PubMed Web of Science ®Google Scholar
• Devita VT, Young RC, Canellos GP. Combination versus single agent chemotherapy: a review of the basis for selection of drug treatment of cancer. Cancer. 1975;35:98–110. doi: 10.1002/1097-0142(197501)35:1<98:AID-CNCR2820350115>3.0.CO;2-B
   PubMed Web of Science ®Google Scholar
• Candelaria M, DueñDueñAs-Gonzalez A. Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma. Ther Adv Hematol. 2021;12:204062072198957. doi: 10.1177/2040620721989579
   Web of Science ®Google Scholar
• Ansell SM, Radford J, Connors JM, et al. Overall survival with brentuximab vedotin in stage III or IV hodgkin’s lymphoma. N Engl J Med. 2022;387(4):310–320. doi: 10.1056/NEJMoa2206125
   PubMed Web of Science ®Google Scholar
• Duenas-Gonzalez A, Gonzalez-Fierro A. Barriers for pharmaceutical innovation with focus in cancer drugs, the case of Mexico. Ther Innov Regul Sci. 2020;54(2):342–352. doi: 10.1007/s43441-019-00062-w
   PubMed Web of Science ®Google Scholar
• Gonzalez-Fierro A, DueñDueñAs-González A. Drug repurposing for cancer therapy, easier said than done. Semin Cancer Biol. 2021;68:123–131. doi: 10.1016/j.semcancer.2019.12.012
   PubMed Web of Science ®Google Scholar
• Gonzalez-Fierro A, Romo-Pérez A, Chávez-Blanco A, et al. Does therapeutic repurposing in cancer meet the expectations of having drugs at a lower price? Clin Drug Investig. 2023;43(4):227–239. doi: 10.1007/s40261-023-01251-0
   PubMed Web of Science ®Google Scholar
• Baker NC, Ekins S, Williams AJ, et al. A bibliometric review of drug repurposing. Drug Discov Today. 2018;23:661–672. doi: 10.1016/j.drudis.2018.01.018
   PubMed Web of Science ®Google Scholar
• Kast RE, Boockvar JA, Brüning A, et al. A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the international initiative for accelerated improvement of glioblastoma care. Oncotarget. 2013;4(4):502–530. doi: 10.18632/oncotarget.969
   PubMedGoogle Scholar
• Halatsch M-E, Dwucet A, Schmidt CJ, et al. In Vitro and clinical compassionate use experiences with the drug-repurposing approach CUSP9v3 in Glioblastoma. Pharmaceuticals. 2021;14(12):1241. doi: 10.3390/ph14121241
   Web of Science ®Google Scholar
• Kast RE, Skuli N, Cos S, et al. The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy. Breast Cancer Targets Ther. 2017;9:495–514. doi: 10.2147/BCTT.S139963
   PubMed Web of Science ®Google Scholar
• Block KI. Life Over Cancer. 1st ed. (NY): Bantam; 2009.
   Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi: 10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Block KI, Gyllenhaal C, Lowe L, et al. Designing a broad-spectrum integrative approach for cancer prevention and treatment. Semin Cancer Biol. 2015;35:S276–304. doi: 10.1016/j.semcancer.2015.09.007
   PubMed Web of Science ®Google Scholar
• Tripathi SC, Fahrmann JF, Vykoukal JV, et al. Targeting metabolic vulnerabilities of cancer: small molecule inhibitors in clinic. Cancer Rep. 2019 2;2(1). doi: 10.1002/cnr2.1131
   Google Scholar
• Romo-Perez A, Dominguez-Gomez G, Chavez-Blanco A, et al. Progress in metabolic studies of gastric cancer and therapeutic implications. Curr Cancer Drug Targets. 2022;22:703–716. doi: 10.2174/1568009622666220413083534
   PubMed Web of Science ®Google Scholar
• Xiao Y, Yu T-J, Xu Y, et al. Emerging therapies in cancer metabolism. Cell Metab. 2023;35:1283–1303. doi: 10.1016/j.cmet.2023.07.006
   PubMed Web of Science ®Google Scholar
• Cervantes-Madrid D, Romero Y, DueñDueñAs-González A. Reviving lonidamine and 6-Diazo-5-oxo-L-norleucine to Be used in combination for metabolic cancer therapy. Biomed Res Int. 2015;2015:1–13. doi: 10.1155/2015/690492
   Web of Science ®Google Scholar
• Kelly W, Diaz Duque AE, Michalek J, et al. Phase II Investigation of TVB-2640 (Denifanstat) with bevacizumab in patients with first relapse high-grade astrocytoma. Clin Cancer Res. 2023;29:2419–2425. doi: 10.1158/1078-0432.CCR-22-2807
   PubMed Web of Science ®Google Scholar
• Romo-Perez A, Dominguez-Gomez G, Chavez-Blanco A, et al. BAPST. A combo of common use drugs as metabolic therapy for cancer: a theoretical proposal. Curr Mol Pharmacol. 2022;15(6):815–831. doi: 10.2174/1874467214666211006123728
   PubMed Web of Science ®Google Scholar
• Zadra G, Photopoulos C, Loda M. The fat side of prostate cancer. Biochim Biophys Acta - Mol Cell Biol Lipids. 2013;1831:1518–1532. doi: 10.1016/j.bbalip.2013.03.010
   PubMed Web of Science ®Google Scholar
• von Eyben, Fe, Kairemo K, von Eyben FE. Acquisition with 11C-choline and 18F-fluorocholine PET/CT for patients with biochemical recurrence of prostate cancer: a systematic review and meta-analysis. Ann Nucl Med. 2016;30(6):385–392. doi: 10.1007/s12149-016-1078-7
   PubMed Web of Science ®Google Scholar
• Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007;7(10):763–777. doi: 10.1038/nrc2222
   PubMed Web of Science ®Google Scholar
• Van Blarigan EL, Kenfield SA, Yang M, et al. Fat intake after prostate cancer diagnosis and mortality in the Physicians’ Health Study. Cancer Causes Control. 2015;26(8):1117–1126. doi: 10.1007/s10552-015-0606-4
   PubMed Web of Science ®Google Scholar
• Romo-Perez A, Domínguez-Gómez G, Chávez-Blanco A, et al. PaSTe. Blockade of the lipid phenotype of prostate cancer as metabolic therapy: a theoretical proposal. Curr Med Chem. 2023;31(22):3265–3285. doi: 10.2174/0929867330666230607104441
   Web of Science ®Google Scholar
• Kendir C, van den Akker M, Vos R, et al. Cardiovascular disease patients have increased risk for comorbidity: a cross-sectional study in the Netherlands. Eur J Gen Pract. 2018;24:45–50. doi: 10.1080/13814788.2017.1398318
   PubMed Web of Science ®Google Scholar
• Schcolnik-Cabrera A, Chávez-Blanco A, Domínguez-Gómez G, et al. Understanding tumor anabolism and patient catabolism in cancer-associated cachexia. Am J Cancer Res. 2017;7(5):1107–1135.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis. 2013;4(3):e532. doi: 10.1038/cddis.2013.60
   PubMed Web of Science ®Google Scholar
• Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116(7):1793–1801. doi: 10.1172/JCI29069
   PubMed Web of Science ®Google Scholar
• Schcolnik-Cabrera A, Chavez-Blanco A, Dominguez-Gomez G, et al. Pharmacological inhibition of tumor anabolism and host catabolism as a cancer therapy. Sci Rep. 2021;11(1):5222. doi: 10.1038/s41598-021-84538-6
   PubMed Web of Science ®Google Scholar
• Wright TJ, Dillon EL, Durham WJ, et al. A randomized trial of adjunct testosterone for cancer-related muscle loss in men and women. J Cachexia Sarcopenia Muscle. 2018;9(3):482–496. doi: 10.1002/jcsm.12295
   PubMed Web of Science ®Google Scholar
• Scott JM, Dillon EL, Kinsky M, et al. Effects of adjunct testosterone on cardiac morphology and function in advanced cancers: an ancillary analysis of a randomized controlled trial. BMC Cancer. 2019;19(1):778. doi: 10.1186/s12885-019-6006-5
   PubMed Web of Science ®Google Scholar
• Robles-Bañuelos B, Romo-Perez A, Domingues-Gomez G, et al. Selection of clinically relevant drug concentrations for in vitro studies of candidates drugs for cancer repurposing -a proposal. Clin Transl Oncol. 2024. May; 26(5): 1077–1088.
   PubMed Web of Science ®Google Scholar